The place of pemetrexed in the management of non-small-cell lung cancer patients

By Tomasini Pascale   Greillier Laurent   Khobta Nataliya   Barlesi Fabrice  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 3, 2013-03 ,pp. : 257-266

Informa Healthcare

Access to resources Recommend Favorite

Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds

By Huang Yu   Chen Yu   Mei Qin   Chen Yuan   Yu Shiying   Xia Shu  

Oncology Reports, Vol. 29, Iss. 6, 2013-06 ,pp. : 2486-2492

Spandidos Publications

Access to resources Recommend Favorite

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer

By Li Zhanxia  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 572-577

Humana Press, Inc

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong   Lin Chia-Chi   Yang James Chih-Hsin  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003

Future Medicine

Access to resources Recommend Favorite